The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials | Zendy

Simin Fan | Zendy; Xiaoyan Shi | Zendy; Jiaxi Yao | Zendy; Min Zhong | Zendy; Peimin Feng | Zendy

Open Access

The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

Author(s) -

Simin Fan,

Xiaoyan Shi,

Jiaxi Yao,

Min Zhong,

Peimin Feng

Publication year - 2020

Publication title -

revista española de enfermedades digestivas

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.331

H-Index - 38

eISSN - 2340-4167

pISSN - 1130-0108

DOI - 10.17235/reed.2020.6392/2019

Subject(s) - meta analysis , randomized controlled trial , fatty liver , medicine , alcoholic liver disease , glucagon like peptide 1 , glucagon like peptide 1 receptor , disease , pharmacology , endocrinology , receptor , type 2 diabetes , diabetes mellitus , agonist , cirrhosis

non-alcoholic fatty liver disease (NAFLD) is considered as the hepatic manifestation of metabolic syndrome and is highly prevalent all over the world. New drugs are urgently needed for the treatment of NAFLD. The aim of this meta-analysis was to assess the efficacy of glucagon-like peptide 1 receptor agonists (GLP-1RAs) in patients with NAFLD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research